Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alterity Therapeutics Limited - American Depositary Shares
(NQ:
ATHE
)
4.420
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alterity Therapeutics Limited - American Depositary Shares
< Previous
1
2
3
4
5
6
7
Next >
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 04, 2023
Via
Benzinga
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease
December 04, 2023
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy
November 27, 2023
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
November 23, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
November 23, 2023
Via
Benzinga
Why Urban Outfitters Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
November 22, 2023
Shares of Urban Outfitters, Inc. (NASDAQ: URBN) dipped during Wednesday’s session after the company reported third-quarter financial results.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
November 22, 2023
Via
Benzinga
Dow Surges 150 Points; US Jobless Claims Decline Sharply
November 22, 2023
U.S. stocks traded higher this morning, with the Dow Jones index gaining around 150 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.43% to 35,239.40 while the NASDAQ...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 22, 2023
Via
Benzinga
Why Guess? Shares Are Trading Lower By Around 15%; Here Are 20 Stocks Moving Premarket
November 22, 2023
Shares of Guess?, Inc. (NYSE: GES) shares dipped in pre-market trading after the company reported worse-than-expected third-quarter financial results and issued fourth-quarter adjusted EPS guidance...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
November 22, 2023
Pre-market stock movers are a hot topic on Wednesday as we check out all of the biggest movements happening this morning!
Via
InvestorPlace
Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434
November 16, 2023
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy
November 08, 2023
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Appendix 4C – Q1 FY24 Quarterly Cash Flow Report
October 30, 2023
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder
August 31, 2023
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson’s and Alzheimer’s
August 23, 2023
New Patent Covers Over 150 Novel Compounds
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson’s Disease and Movement Disorders
August 22, 2023
Presentations Highlight New Data on Diagnostic Accuracy and Novel Biomarkers of Disease Severity in Multiple System Atrophy
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund
August 15, 2023
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Appendix 4C – Q4 FY23 Quarterly Cash Flow Report
July 31, 2023
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned
July 26, 2023
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023
June 21, 2023
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
June 12, 2023
Via
Benzinga
Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder
May 30, 2023
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023
May 19, 2023
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
May 17, 2023
Via
Benzinga
Appendix 4C – Q3 FY23 Quarterly Cash Flow Report
May 10, 2023
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy
May 10, 2023
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology
April 26, 2023
Wearable sensor parameters correlate strongly with clinical scales of motor impairment
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Enrolls First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
April 04, 2023
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
March 16, 2023
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.